BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016;17. [PMID: 27187363 DOI: 10.3390/ijms17050714] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Li S, Zhang Z, Yu K, Duan X, Long L, Zhang S, Jiang M, Liu O. Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Indian J Dermatol 2020;65:274-8. [PMID: 32831367 DOI: 10.4103/ijd.IJD_217_19] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vargas JI, Arab JP, Bessone F, Lucena MI, Andrade RJ, Arrese M. Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. Curr Hepatology Rep 2017;16:286-92. [DOI: 10.1007/s11901-017-0380-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Danan G, Teschke R. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch? Drug Saf. 2018;41:735-743. [PMID: 29502198 DOI: 10.1007/s40264-018-0654-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
4 Benesic A, Rotter I, Dragoi D, Weber S, Leitl A, Buchholtz ML, Gerbes AL. Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 2018;16:1488-1494.e5. [PMID: 29723689 DOI: 10.1016/j.cgh.2018.04.049] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
5 McEuen K, Borlak J, Tong W, Chen M. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.Int J Mol Sci. 2017;18. [PMID: 28640208 DOI: 10.3390/ijms18071335] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
6 Xiao LL, Zhang F, Zhao YL, Zhang LJ, Xie ZY, Huang KZ, Ouyang XX, Wu XX, Xu XW, Li LJ. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci Rep 2020;10:18128. [PMID: 33093629 DOI: 10.1038/s41598-020-75141-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 66.0] [Reference Citation Analysis]
8 Nguyen PTT, Hoang DV, Pham KM, Nguyen HT. A Multiple Logistic Regression Model Based on Gamma-Glutamyl Transferase as a Biomarker for Early Prediction of Drug-Induced Liver Injury in Vietnamese Patients. J Clin Pharmacol 2022;62:110-7. [PMID: 34415063 DOI: 10.1002/jcph.1955] [Reference Citation Analysis]
9 Yang HY, Guo DH, Jia WP, Zhu M, Xu YJ, Wang XY. Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study. Ther Clin Risk Manag 2019;15:389-95. [PMID: 30881004 DOI: 10.2147/TCRM.S195802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tang H, Long N, Dai M, Lin L, Li J, Sun F, Guo L. Effect of citral on mouse hepatic cytochrome P450 enzymes. Pharm Biol 2018;56:337-43. [PMID: 29969356 DOI: 10.1080/13880209.2018.1470191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Li DK, Chen J, Ge ZZ, Sun ZX. Hepatotoxicity in Rats Induced by Aqueous Extract of Polygoni Multiflori Radix, Root of Polygonum multiflorum Related to the Activity Inhibition of CYP1A2 or CYP2E1. Evid Based Complement Alternat Med 2017;2017:9456785. [PMID: 28626488 DOI: 10.1155/2017/9456785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
12 Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf. 2016;39:729-744. [PMID: 27091053 DOI: 10.1007/s40264-016-0423-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
13 Liu YH, Guo Y, Xu H, Feng H, Chen DY. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist 2021;14:3667-71. [PMID: 34526786 DOI: 10.2147/IDR.S326386] [Reference Citation Analysis]
14 Watkins PB. Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications. Adv Pharmacol 2019;85:165-93. [PMID: 31307586 DOI: 10.1016/bs.apha.2019.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. Drug-induced liver injury. Nat Rev Dis Primers 2019;5:58. [PMID: 31439850 DOI: 10.1038/s41572-019-0105-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 27.0] [Reference Citation Analysis]
16 Honda S, Sawada K, Hasebe T, Nakajima S, Fujiya M, Okumura T. Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. World J Gastroenterol 2017; 23(31): 5823-5828 [PMID: 28883709 DOI: 10.3748/wjg.v23.i31.5823] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
18 Mahmoud MAM, Yahia D, Abdel-Magiud DS, Darwish MHA, Abd-Elkareem M, Mahmoud UT. Broiler welfare is preserved by long-term low-dose oral exposure to zinc oxide nanoparticles: preliminary study. Nanotoxicology 2021;15:605-20. [PMID: 33792477 DOI: 10.1080/17435390.2021.1905099] [Reference Citation Analysis]
19 Bai F, Du W, Liu X, Su L, Li Z, Chen T, Ge X, Li Q, Yang H, Song J. A NO-Responsive Ratiometric Fluorescent Nanoprobe for Monitoring Drug-Induced Liver Injury in the Second Near-Infrared Window. Anal Chem 2021;93:15279-87. [PMID: 34748309 DOI: 10.1021/acs.analchem.1c02238] [Reference Citation Analysis]
20 Benesic A, Jalal K, Gerbes AL. Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences 2019;171:296-302. [DOI: 10.1093/toxsci/kfz156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 He S, Ye T, Wang R, Zhang C, Zhang X, Sun G, Sun X. An In Silico Model for Predicting Drug-Induced Hepatotoxicity. Int J Mol Sci 2019;20:E1897. [PMID: 30999595 DOI: 10.3390/ijms20081897] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
22 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
23 Andrade RJ, Robles‐díaz M. Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice. Liver Int 2019;40:6-17. [DOI: 10.1111/liv.14271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
24 Spernovasilis N, Kofteridis DP. Pre-Existing Liver Disease and Toxicity of Antifungals. J Fungi (Basel) 2018;4:E133. [PMID: 30544724 DOI: 10.3390/jof4040133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
25 Teschke R, Andrade RJ. Drug, Herb, and Dietary Supplement Hepatotoxicity. Int J Mol Sci 2016;17:E1488. [PMID: 27608014 DOI: 10.3390/ijms17091488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
26 Ma H, Chen S, Xiong H, Wang M, Hang W, Zhu X, Zheng Y, Ge B, Li R, Cui H. Astaxanthin from Haematococcus pluvialis ameliorates the chemotherapeutic drug (doxorubicin) induced liver injury through the Keap1/Nrf2/HO-1 pathway in mice. Food Funct 2020;11:4659-71. [DOI: 10.1039/c9fo02429h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
27 Ivashkin VT, Baranovsky AY, Raikhelson KL, Palgova LK, Maevskaya MV, Kondrashina EA, Marchenko NV, Nekrasova TP, Nikitin IG. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2019;29:101-31. [DOI: 10.22416/1382-4376-2019-29-1-101-131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
28 Becker MW, Schwambach KH, Lunardelli M, Blatt CR. Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence? World J Gastrointest Pharmacol Ther 2021; 12(3): 40-55 [PMID: 34046243 DOI: 10.4292/wjgpt.v12.i3.40] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gervasoni C, Cattaneo D, Filice C, Galli M; “Gruppo Italiano Studio-NASH in malattie infettive”. Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res 2019;145:104267. [PMID: 31077811 DOI: 10.1016/j.phrs.2019.104267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
30 Girish C, Sanjay S. Role of immune dysfunction in drug induced liver injury. World J Hepatol 2021; 13(11): 1677-1687 [PMID: 34904037 DOI: 10.4254/wjh.v13.i11.1677] [Reference Citation Analysis]
31 Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154-64. [PMID: 28341748 DOI: 10.1136/gutjnl-2016-313369] [Cited by in Crossref: 196] [Cited by in F6Publishing: 176] [Article Influence: 39.2] [Reference Citation Analysis]
32 Teschke R, Danan G. Causality Assessment Methods in Drug-Induced Liver Injury. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 555-94. [DOI: 10.1007/978-1-4939-7677-5_27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
33 Habte ML, Melka DS, Degef M, Menon MKC, Yifter H, Feyisa TO. Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy. Diabetes Metab Syndr Obes 2020;13:763-73. [PMID: 32256093 DOI: 10.2147/DMSO.S234382] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Ikewuchi CC, Ikewuchi JC, Ifeanacho MO, Jack DP, Ikpe CN, Ehiosun S, Ajayi TB. Protective effect of aqueous leaf extracts of Chromolaena odorata and Tridax procumbens on doxorubicin-induced hepatotoxicity in Wistar rats. Porto Biomed J 2021;6:e143. [PMID: 34881354 DOI: 10.1097/j.pbj.0000000000000143] [Reference Citation Analysis]
35 Li X, Gao P, Niu J. Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury. Biomed Res Int 2019;2019:8764093. [PMID: 31531370 DOI: 10.1155/2019/8764093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]